Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

被引：0
作者：
Marta Milà-Alomà
Mahnaz Shekari
Gemma Salvadó
Juan Domingo Gispert
Eider M. Arenaza-Urquijo
Grégory Operto
Carles Falcon
Natalia Vilor-Tejedor
Oriol Grau-Rivera
Aleix Sala-Vila
Gonzalo Sánchez-Benavides
José Maria González-de-Echávarri
Carolina Minguillon
Karine Fauria
Aida Niñerola-Baizán
Andrés Perissinotti
Maryline Simon
Gwendlyn Kollmorgen
Henrik Zetterberg
Kaj Blennow
Marc Suárez-Calvet
José Luis Molinuevo
机构：
[1] Pasqual Maragall Foundation,Barcelonaβeta Brain Research Center (BBRC)
[2] IMIM (Hospital del Mar Medical Research Institute),Centro de Investigación Biomédica en Red Bioingeniería
[3] Universitat Pompeu Fabra,Centre for Genomic Regulation (CRG)
[4] Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES),Department of Clinical Genetics
[5] Biomateriales y Nanomedicina,Servei de Neurologia
[6] The Barcelona Institute for Science and Technology,Servei de Medicina Nuclear
[7] ERASMUS MC,Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology
[8] Hospital del Mar,Clinical Neurochemistry Laboratory
[9] Hospital Clínic,Department of Neurodegenerative Disease
[10] Roche Diagnostics International Ltd.,undefined
[11] Roche Diagnostics GmbH,undefined
[12] University of Gothenburg,undefined
[13] Sahlgrenska University Hospital,undefined
[14] UCL Institute of Neurology,undefined
[15] UK Dementia Research Institute at UCL,undefined
[16] Present address: H. Lundbeck A/S,undefined
来源：
Alzheimer's Research & Therapy | / 13卷
关键词：
Preclinical; Alzheimer’s disease; CSF; Biomarkers; Subthreshold; Cognitively unimpaired;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 429 条
  • [1] Dubois B(2014)Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria Lancet Neurol 13 614-629
  • [2] Feldman HH(2011)Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 7 280-292
  • [3] Jacova C(2018)NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease Alzheimers Dement 14 535-562
  • [4] Hampel H(2016)Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria Alzheimers Dement 12 292-323
  • [5] Molinuevo JL(2019)Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease Ther Adv Neurol Disord 12 175628641988881-654
  • [6] Blennow K(2019)Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum Alzheimers Dement 15 644-684
  • [7] DeKosky ST(2016)CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis Lancet Neurol 15 673-804
  • [8] Gauthier S(2014)Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease Sci Transl Med 6 226ra30-2033
  • [9] Selkoe D(2012)Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 367 795-79
  • [10] Bateman R(2015)Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation Brain. 138 2020-4489
12345678910